About HSAS

The term ‘arterial stiffness’ has been known and used in cardiovascular medicine for many years. It literally means that the artery walls become rigid.
Our busy world, the adverse effects of civilization, the – sometimes cumulative – presence of risk factors even at young age (smoking, hypertension, diabetes, hyperlipidemia, obesity) can cause premature aging and increased stiffness of blood vessels. Consequences of increased arterial stiffness are vascular diseases even at a young age (calcification, stenosis or even obstruction of the carotid, limb and coronary arteries), which can lead to stroke, myocardial infarction or sudden death.
The development of atherosclerosis and symptomatic vascular disease takes decades. Therefore, it would be advisable for individuals at risk to be identified, investigated and treated at an early stage to stop and reverse early atherosclerosis, thus avoid the infarction expected in even 5 or 10 years. Our goal is to fully screen those asymptomatic individuals at medium risk (‘only’ 2-3 risk factors), for whom, based on the current risk assessment, the real risk and the task cannot be accurately estimated. Their vascular condition can be very different. However, a very large proportion of the healthy-considered population also belongs to this category. It is well-known that the rate of cardiovascular disease is very high in Hungary, one in two people dying as a result. Almost half of Hungarian males die before the age of 60!
Examination of vasodilatation has been brought into focus of clinical interest in the recent years, one reason being the increasing availability of data on the independent prognostic and risk-predictive role of arterial stiffness parameters. On the other hand, there are more and more methods available to screen them. By doing so, we are able to better assess the cardiovascular risk of an individual, and to detect and treat atherosclerosis even in a subclinical stage. The CAFE sub-study of the ASCOT study has clearly highlighted its importance, which revealed that it actually matters what type of antihypertensive treatment is used to treat high blood pressure, as different agents provide different protection against cardiovascular complications, despite having the same reductive effect on (peripheral) blood pressure. The explanation is that different agents have different effects on arterial stiffness and central blood pressure.
These thoughts have driven us to found the Hungarian Society of Arterial Stiffness in late 2006. Our main goal is to make cardiovascular prevention more effective by cooperating with the leading medical scientific societies. Our name expresses the interdisciplinary endeavor to combat atherosclerosis and its complications by examining vasodilatation and effectively screening the endangered population.
We believe that it is not enough to recognize and treat the ‘classic’ risk factors, as in many cases they do not predict e.g. why a relatively young patient had an infarction with normal blood pressure and cholesterol level. However, a functional screening test (vascular dilatation test) can assess the condition of the vessels, and the pathologic medical report can be used to identify individuals whose vascular system should be further investigated by morphological examination (carotid ultrasound, cardio-CT, coronarography, etc.), so there is a good chance of preventing the imminent vascular catastrophe with appropriate therapy in the case of asymptomatic atherosclerosis.
If you are committed to cardiovascular prevention based on your job, area of expertise, or interest and agree with our efforts, please join us, because it would greatly contribute to our primary goal of reducing cardiovascular morbidity and mortality in Hungary.